Document Type
Article
Publication Date
9-6-2024
Abstract
The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.
Recommended Citation
Al-Juhaishi, Taha; Dela Cruz, Servillano; Gupta, Rohan; Keiffer, Gina; Morrison, Vicki; Shapira, Iuliana; Woods, Ashley; Norsworthy, Kelly; de Claro, Romeo Angelo; Theoret, Marc; Garg, Ravin; and Pulte, Elizabeth Dianne, "Treatment of Acute Myeloid Leukemia in the Community Setting" (2024). Kimmel Cancer Center Faculty Papers. Paper 135.
https://jdc.jefferson.edu/kimmelccfp/135
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
39159003
Language
English
Comments
This article is the author's final published version in The oncologist, Volume 29, Issue 9, September 2024, Pages 801 - 805.
The published version is available at https://doi.org/10.1093/oncolo/oyae051.
Copyright © The Author(s) 2024